GSK Unlikely to Face Material Impact from AnaptysBio Litigation -- Market Talk
Dow Jones
Yesterday
1227 GMT - GSK is unlikely to take a financial hit from litigation with AnaptysBio over the Jemperli license, J.P. Morgan analysts write. The U.K. drugmaker's cancer treatment accounts for only about 1% of its net present value in their model, the analysts say. GSK already boosted the royalties it pays to the U.S. biotech group in a 2020 settlement to what is a fair, attractive level, the analysts write. More details from the court case will be needed to fully assess the outcome, they add. Shares are up 0.2% at 1,764.5 pence and up 31% year-to-date. (william.gray@wsj.com)
(END) Dow Jones Newswires
November 21, 2025 07:28 ET (12:28 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.